Clinical Trial

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated April 21, 2026 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific MTAP-deleted tumor types. The study drug, TNG462, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 225 participants.
Protocol Amendment History 29 amendments
This ClinicalTrials.gov record has been amended 29 times since 2023-02-07; most recent amendment 2026-04-17.
Status change: Not Yet Recruiting → Recruiting 2023-06-07
Trial Details
NCT Number NCT05732831
Lead Sponsor Tango Therapeutics, Inc.
Conditions Locally Advanced Solid Tumor
Enrollment 225 participants
Start Date 2023-05-26
Primary Completion 2026-05 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2026-04-21